<DOC>
	<DOCNO>NCT01374841</DOCNO>
	<brief_summary>The purpose study determine engraftment achieve safely patient high-risk hematologic malignancy undergo non-myeloablative transplant peripheral stem cell Human Leukocyte Antigen ( HLA ) haploidentical donor pre post-transplant cyclophosphamide immunosuppression .</brief_summary>
	<brief_title>Hematopoietic Cell Transplantation Patients With Hematologic Malignancies Using Related , HLA-Haploidentical Donors</brief_title>
	<detailed_description>It important extend option nonmyeloablative , hematopoietic stem cell transplantation ( HSCT ) potential therapy hematologic malignancy patient HLA-matched donor . Almost patient would relate donor identical one HLA haplotype ( haploidentical ) mismatch HLA-A , B DR unshared haplotype . Thus far , nonmyeloablative HSCT HLA-mismatched donor associate high rate graft failure graft-versus-host disease ( GVHD ) . In protocol , use combination immunosuppressive agent include cyclophosphamide administer HSCT facilitate engraftment delete highly alloreactive T-cell clone presumably involve GVHD .</detailed_description>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Patients ≤70 year old Eligible diagnosis : CML AP AML highrisk cytogenetics [ del ( 5q ) /5 , del ( 7q ) /7 , abnormal 3q , 9q , 11q , 20q , 21q , 17p , ( 6:9 ) , ( 9 ; 22 ) , complex karyotype ( ≥3 abnormality ) ] CR1 AML ≥ CR2 ; patient &lt; 5 % marrow blast time transplant Highrisk ALL define : CR1 highrisk cytogenetics ( 9 ; 22 ) , ( 8 ; 14 ) , ( 4 ; 11 ) , ( 1 ; 19 ) adult patient &gt; 4 wk achieve CR1 ≥ CR2 Patients &lt; 5 % marrow blast time transplant MDS ( &gt; int1 per IPSS ) ≥ 1 prior cycle induction chemotherapy ; &lt; 5 % marrow blast time transplant MM Stage II III patient progress initial response chemotherapy autologous HSCT MM patient refractory disease may benefit tandem autologousnonmyeloablative allogeneic transplant CLL , NHL HD ineligible autologous HSCT resistant/refractory disease may benefit tandem autologous nonmyeloablative allogeneic transplant . Patients receive prior allogeneic HSCT either reject graft become tolerant graft active GvHD require immunosuppressive therapy could enrol Patients suitably match related unrelated donor Patients conventional transplant option ( conventional transplant priority eligible patient ≤ 50 yr age relate donor mismatch single HLAA , B DRB1 antigen ) CNS involvement disease refractory intrathecal chemotherapy Presence active , serious infection ( e.g. , mucormycosis , uncontrolled aspergillosis , tuberculosis ) Karnofsky Performance Status &lt; 60 % adult patient ( Appendix A ) Patients follow organ dysfunction : Left ventricular ejection fraction &lt; 35 % DLCO &lt; 35 % and/or receive supplemental continuous oxygen Liver abnormality : fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evidence prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL symptomatic biliary disease . HIVpositive patient Women childbearing potential pregnant ( βHCG+ ) breast feed Fertile men woman unwilling use contraceptive 12 month post transplant Life expectancy severely limited disease malignancy Patients investigational drug time enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>High-Risk Hematologic Neoplasms</keyword>
	<keyword>Haploidentical Donors</keyword>
	<keyword>Cyclophosphamide</keyword>
</DOC>